

Influenza Session

Robert L. Atmar, MD
Chair, Influenza Work Group

Advisory Committee on Immunization Practices
October 23, 2019

Influenza Work Group

ACIP Members

Robert Atmar (Chair)

Kevin Ault

Hank Bernstein

Peter Szilagyi

Keipp Talbot

***Ex Officio* Members**

Michael Cooper (NIH)

Cynthia Nolletti (FDA)

Chris Roberts (NIH)

Susan Wollersheim (FDA)

Consultants

Ed Belongia

Jeff Duchin

Wendy Keitel

Jamie Loehr

Kathy Neuzil

Liaison Representatives

Sarah Coles (AAFP)

Buddy Creech (PIDS)

Sarah Despres (Consumer Representative)

Sandra Fryhofer (ACP; AMA)

Ian Gemmill (NACI)

Denise Jamieson (ACOG)

Marie-Michèle Léger (AAPA)

Susan Lett (CSTE)

Flor Munoz (AAP)

William Schaffner (NFID)

Rob Schechter (AIM)

Ken Schmader (AGS)

Patsy Stinchfield (NAPNAP)

Tamara Sheffield (AHIP)

Kelsey Young (NACI)

Matthew Zahn (NACCHO)

Recap of Influenza Session, June 2019

- Influenza surveillance and vaccine effectiveness updates
- Overview of 2018-19 influenza vaccine safety surveillance
- Proposed recommendations for the 2019-20 influenza season

Work Group Activities and Discussion Since June 2019

- 2019-20 ACIP Influenza Statement Published August 23, 2019
- Series of discussions to develop protocol for systematic review of influenza vaccines for older adults
 - Selection of relevant comparisons and outcomes
- Presentation of Phase 3 trial data for quadrivalent high-dose inactivated influenza vaccine for persons 65 years of age and over
 - Fluzone High-Dose (trivalent high-dose inactivated influenza vaccine) licensed for this population since 2009)

Agenda Overview

- **U.S. Influenza Activity Update**
 - Ms. Lynnette Brammer, CDC/NCIRD
- **QIV-HD Clinical Development and Phase 3 Safety and Immunogenicity Study Results**
 - Dr. Lee-Jah Chang, Sanofi Pasteur
- **Summary and Work Group Considerations**
 - Dr. Lisa Grohskopf, CDC/NCIRD